INSM – Insmed Incorporated
Insmed IncorporatedINSM
$73.62Name : Insmed Incorporated
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $13,409,074,176.00
EPSttm : -5.93
Insmed Incorporated
$73.62
1.21%$0.88Float Short %
9.25
Margin Of Safety %
Put/Call OI Ratio
1.16
EPS Next Q Diff
0.06
EPS Last/This Y
0.41
EPS This/Next Y
1.6
Price
73.59
Target Price
97
Analyst Recom
1.05
Performance Q
-1.7
Relative Volume
0.68
Beta
0.79
Ticker: INSM
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-05-08 | INSM | 65.63 | 0.95 | 0.55 | 70058 |
| 2025-05-09 | INSM | 65.08 | 0.95 | 0.82 | 72341 |
| 2025-05-12 | INSM | 67.78 | 0.94 | 5.02 | 74432 |
| 2025-05-13 | INSM | 65.69 | 0.94 | 2.53 | 74338 |
| 2025-05-14 | INSM | 65.61 | 1.02 | 1.91 | 79898 |
| 2025-05-15 | INSM | 67.17 | 1.01 | 21.94 | 81464 |
| 2025-05-16 | INSM | 68.15 | 0.99 | 0.57 | 80909 |
| 2025-05-19 | INSM | 67.86 | 1.07 | 0.56 | 68676 |
| 2025-05-20 | INSM | 68.49 | 1.07 | 0.20 | 69082 |
| 2025-05-21 | INSM | 66.03 | 1.06 | 7.27 | 69660 |
| 2025-05-22 | INSM | 66.17 | 1.11 | 0.51 | 71472 |
| 2025-05-23 | INSM | 67.53 | 1.07 | 2.28 | 74402 |
| 2025-05-27 | INSM | 68.05 | 1.08 | 0.35 | 74999 |
| 2025-05-28 | INSM | 66.37 | 1.09 | 1.51 | 75353 |
| 2025-05-29 | INSM | 69.2 | 1.09 | 0.51 | 75558 |
| 2025-05-30 | INSM | 69.71 | 1.09 | 0.73 | 76773 |
| 2025-06-02 | INSM | 71.7 | 1.09 | 4.15 | 78184 |
| 2025-06-03 | INSM | 73.08 | 1.11 | 6.69 | 79723 |
| 2025-06-04 | INSM | 73.69 | 1.21 | 0.54 | 83249 |
| 2025-06-05 | INSM | 72.74 | 1.14 | 1.47 | 87562 |
| 2025-06-06 | INSM | 73.78 | 1.16 | 0.07 | 88493 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-05-08 | INSM | 65.68 | -28.4 | -42.0 | -5.32 |
| 2025-05-09 | INSM | 65.08 | 30.4 | -70.0 | -4.66 |
| 2025-05-12 | INSM | 67.75 | 30.4 | -115.5 | -4.66 |
| 2025-05-13 | INSM | 65.71 | 31.1 | -7.4 | -5.05 |
| 2025-05-14 | INSM | 65.61 | 33.1 | -35.2 | -5.05 |
| 2025-05-15 | INSM | 67.15 | 33.1 | -9.5 | -5.05 |
| 2025-05-16 | INSM | 68.16 | 33.1 | -0.8 | -5.05 |
| 2025-05-19 | INSM | 67.88 | 32.9 | 15.3 | -5.11 |
| 2025-05-20 | INSM | 68.51 | 32.3 | 3.6 | -5.16 |
| 2025-05-21 | INSM | 66.01 | 32.3 | 45.7 | -5.16 |
| 2025-05-22 | INSM | 66.20 | 32.3 | 9.6 | -5.16 |
| 2025-05-23 | INSM | 67.51 | 32.3 | -6.7 | -5.16 |
| 2025-05-27 | INSM | 68.02 | 32.3 | 5.5 | -5.16 |
| 2025-05-28 | INSM | 66.37 | 32.3 | 34.4 | -5.16 |
| 2025-05-29 | INSM | 69.20 | 32.3 | -27.3 | -5.16 |
| 2025-05-30 | INSM | 69.73 | 32.3 | 5.2 | -5.16 |
| 2025-06-02 | INSM | 71.68 | 32.3 | -13.6 | -5.16 |
| 2025-06-03 | INSM | 73.08 | 32.3 | -5.9 | -5.16 |
| 2025-06-04 | INSM | 73.70 | 32.3 | 4.3 | -5.16 |
| 2025-06-05 | INSM | 72.74 | 32.3 | 24.0 | -5.16 |
| 2025-06-06 | INSM | 73.59 | 32.4 | 1.4 | -5.16 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-05-08 | INSM | -16.72 | 2.30 | 8.49 |
| 2025-05-09 | INSM | -16.72 | 2.30 | 8.49 |
| 2025-05-12 | INSM | -16.72 | 1.25 | 8.85 |
| 2025-05-13 | INSM | -16.72 | 1.25 | 8.85 |
| 2025-05-14 | INSM | -16.70 | 1.25 | 8.85 |
| 2025-05-15 | INSM | -14.22 | 1.25 | 8.90 |
| 2025-05-16 | INSM | -14.22 | 1.25 | 8.90 |
| 2025-05-19 | INSM | -17.90 | 2.65 | 8.86 |
| 2025-05-20 | INSM | -17.09 | 2.65 | 8.86 |
| 2025-05-21 | INSM | -17.09 | 2.65 | 8.86 |
| 2025-05-22 | INSM | -17.09 | 2.65 | 8.86 |
| 2025-05-23 | INSM | -17.52 | 2.65 | 8.86 |
| 2025-05-27 | INSM | -16.95 | 3.79 | 8.87 |
| 2025-05-28 | INSM | -17.01 | 3.79 | 9.25 |
| 2025-05-29 | INSM | -17.01 | 3.79 | 9.25 |
| 2025-05-30 | INSM | -17.01 | 3.79 | 9.25 |
| 2025-06-02 | INSM | -17.01 | 4.50 | 9.25 |
| 2025-06-03 | INSM | -17.44 | 4.50 | 9.25 |
| 2025-06-04 | INSM | -17.44 | 4.50 | 9.25 |
| 2025-06-05 | INSM | -17.88 | 4.50 | 9.25 |
| 2025-06-06 | INSM | -17.88 | 4.50 | 9.25 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-1.42
Avg. EPS Est. Current Quarter
-1.31
Avg. EPS Est. Next Quarter
-1.36
Insider Transactions
-17.88
Institutional Transactions
4.5
Beta
0.79
Average Sales Estimate Current Quarter
103
Average Sales Estimate Next Quarter
113
Fair Value
Quality Score
30
Growth Score
53
Sentiment Score
72
Actual DrawDown %
13.3
Max Drawdown 5-Year %
-63.3
Target Price
97
P/E
Forward P/E
PEG
P/S
35.19
P/B
135.05
P/Free Cash Flow
EPS
-5.95
Average EPS Est. Cur. Y
-5.16
EPS Next Y. (Est.)
-3.56
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-265.93
Relative Volume
0.68
Return on Equity vs Sector %
-1045.9
Return on Equity vs Industry %
-1027.9
EPS 1 7Days Diff
-0.1
EPS 1 30Days Diff
0.15
EBIT Estimation
1.4
Insmed IncorporatedSector: Healthcare
Industry: Biotechnology
Employees: 1271
Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of refractory nontuberculous mycobacterial lung infections, as well as is in phase 3 clinical trial for the treatment of mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It also devlops brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1(DPP1) that is in phase 3 clinical trial for the treatment of bronchiectasis; and in phase 2 clinical trial for the treatment of chronic rhinosinusitis without nasal polyps and hidradenitis suppurativa. In addition, the company is developing treprostinil palmitil inhalation powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil, which is in phase 3 clinical trial for the treatment of pulmonary hypertension associated with interstitial lung disease; and phase 2 clinical trial for the treatment of pulmonary arterial hypertension. Further, it develops gene therapy, a microdystrophin adeno-associated virus gene replacement therapy which is in phase 1 clinical trial for the treatment of Duchenne muscular dystrophy, as well as is in pre-clinical development for gene therapy, next generation DPP1 inhibitor, deimmunized therapeutic protein, and synthetic rescue. The company was founded in 1988 and is headquartered in Bridgewater, New Jersey.
stock quote shares INSM – Insmed Incorporated Stock Price stock today
news today INSM – Insmed Incorporated stock forecast ,stock prediction 2023 2024 2025
marketwatch INSM – Insmed Incorporated yahoo finance google finance
stock history INSM – Insmed Incorporated invest stock market
stock prices INSM premarket after hours
ticker INSM fair value insiders trading